Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Economic information and modeling report

Modeling overview

5 evidence topics · 4 sources

Summary: published economic evaluations, HTA status, and commercial forecasts

No published cost-effectiveness analysis, budget impact model, or health technology assessment of inaxaplin or of any other APOL1-targeted therapy was identified, and no ICER review was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. The only APOL1-related economic analysis identified is a “crude cost analysis” of donor genotyping at one center, in which 1 of 26 potential African American living donors had a high-risk genotype. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Guggenheim Securities analysts assigned a 65% probability of success in primary AMKD and 45% in the type 2 diabetes population; Vertex investor relations stated that AMPLITUDE could address about 150,000 people in the U.S. and Europe ; Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000.

Published cost-effectiveness analyses, budget impact models, and HTA reviews of inaxaplin

No evidence found.